Abstract:Background Enfortumab vedotin (EV) is a nectin-4-directed antibody and microtubule inhibitor conjugate indicated for patients with metastatic urothelial carcinoma (mUC) who have received prior platinum-based chemotherapy and PD-1/L1 inhibitors or are ineligible for cisplatin-containing regimens and have undergone at least one prior line of therapy. EV is also indicated in combination with pembrolizumab in the first-line setting. However, real-world effectiveness of EV based on treatment line and impact of prior therapy remains unclear. Methods This retrospective study utilized the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database. Patients with advanced, recurrent, or mUC of upper or lower urinary tract who received single-agent EV in the second-line or beyond after December 18, 2019 (FDA accelerated approval date), were included. Patients without documentation of first-line therapy or without evidence of contact for 90 days from mUC diagnosis were excluded. Time to next therapy (TTNT) and overall survival (OS) were analyzed based on treatment line and prior platinum-based chemotherapy and PD-1/L1 inhibitors using Kaplan-Meier survival estimates and its 95% confidence interval. Results Between January 17, 2020, and September 30, 2022, 6,566 patients with mUC received systemic treatment, with 431 receiving EV. EV monotherapy was administered across various lines (N=371): second (157), third (132), fourth (62), and fifth (20). Approximately 22% of patients had prior platinum-based therapy, and 48% had prior PD-1/L1 inhibitors. Median TTNT and OS varied across treatment lines, with patients with prior platinum exposure generally showing longer TTNT and OS, notably in those receiving EV in the fourth-line setting. Conclusions EV demonstrates efficacy in patients with mUC regardless of prior receipt of platinum-based chemotherapy and PD-1/L1 inhibitors or treatment line. While only hypothesis-generating, these findings provide valuable insights for patient counseling, prognostication, and therapeutic decision-making in clinical practice. Patient Summary In this report, we looked at survival outcomes of patients with advanced urothelial cancer treated with single-agent enfortumab vedotin in a large US-based multi-institutional population. We found that the effectiveness of this agent remained consistent regardless of the number or type of prior systemic therapy. Microabstract Enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, shows efficacy in patients with metastatic urothelial carcinoma (mUC) across various lines of therapy and prior treatments. Real-world data from 371 patients indicate median overall survival (rwOS) ranging from 7.2 to 11 months. EV remains effective irrespective of previous platinum or PD-1/L1 inhibitor therapies, enhancing mUC treatment flexibility.

Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database

Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System

A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin

Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

Novel Insights into Post-Marketing Adverse Events Associated with Lenvatinib: A Comprehensive Analysis Utilizing the FAERS Database

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis

Enfortumab vedotin–related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database

Findings, Considerations, and Future Directions

Real-world effectiveness of single-agent enfortumab vedotin in patients with advanced urothelial carcinoma

Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database

Exploration of enfortumab vedotin (EV)–related cutaneous events by race in two real-world cohorts.

Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database

Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database

Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database

A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617